Sugi Predict

Sugi Predict / Compounds / SCHEMBL410530

SCHEMBL410530

SCHEMBL410530

CCOC(=O)c1cc(C(F)(F)F)on1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ GAA P10253 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ NR1H2 P55055 1/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ MLYCD O95822 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ACR P10323 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24710096 0.89 CYP1A2 (0.44) IDO1CYP1A2GAAHDAC4HDAC6
SCHEMBL3760681 0.89 CYP1A2 (0.44) IDO1CYP1A2GAAHDAC4HDAC6
SCHEMBL13887373 0.86 MLYCD (0.49) IDO1CYP1A2HDAC4HDAC6KMT2A
SCHEMBL352509 0.85 MAPK1 (0.49) CYP1A2KMT2AMEN1MAPTNR1H2
SCHEMBL10044257 0.85 MLYCD (0.43) IDO1CYP1A2HDAC4HDAC6KMT2A
SCHEMBL1807034 0.84 CYP1A2 (0.45) CYP1A2KMT2AMEN1MAPTNR1H2
SCHEMBL15956383 0.82 MAPT (0.45) IDO1CYP1A2MAPTALDH1A1TSHR
SCHEMBL14067391 0.81 CYP1A2 (0.42) CYP1A2GAAKMT2AMEN1MAPT
SCHEMBL23189038 0.81 MAPT (0.47) CYP1A2MAPTALDH1A1TSHRKDM4E
SCHEMBL3250576 0.79 PDK2 (0.47) CYP1A2MAPTALDH1A1KDM4EMLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025038930-A1 AZEPANE AND PYRROLIDINE COMPOUNDS AND USES THEREOF XENON PHARMACEUTICALS, INC. (CA) 2025-02-20 — — WO disclosed
US-20250059171-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 — — US disclosed
WO-2024245156-A1 HETEROCYCLIC COMPOUND ACTING AS α5-GABAA RECEPTOR REGULATOR 武汉人福创新药物研发中心有限公司 2024-12-05 — — WO disclosed
CN-119019425-A Alpha 5-GABAAHeterocyclic compounds as receptor modulators 武汉人福创新药物研发中心有限公司 2024-11-26 — — CN disclosed
EP-4444711-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-10-16 — — EP disclosed
US-12060333-B2 Aminocarbamoyl compounds for the treatment of viral infections HOFFMANN-LA ROCHE INC. (US) 2024-08-13 — — US disclosed
CN-116438160-A Carbamoyl compounds for the treatment of viral infections 豪夫迈·罗氏有限公司 2023-07-14 — — CN disclosed
EP-4204393-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2023-07-05 — — EP disclosed
WO-2023104882-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-15 — — WO disclosed
WO-2022043374-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2022-03-03 — — WO disclosed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — US disclosed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — US disclosed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — US disclosed
WO-2012032018-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — WO disclosed
WO-2012032018-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — WO disclosed
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2005-11-10 — — US disclosed
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-16 — — US disclosed
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-09 — — US disclosed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 — — US disclosed
WO-2003093250-A2 POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR PHARMACIA & UPJOHN COMPANY (US) 2003-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 IDO1 715/4885CYP1A2 1827/4885GAA 2909/4885
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 IDO1 715/4885CYP1A2 1827/4885GAA 2909/4885
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 IDO1 715/4885CYP1A2 1827/4885GAA 2909/4885
US-12060333-B2 Aminocarbamoyl compounds for the treatment of viral infections SARS1, BCAT1, SLC1A5 IDO1 3092/4885CYP1A2 2590/4885GAA 2784/4885
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA7, CHRNA1, CHRNA5 IDO1 1708/4885CYP1A2 1913/4885GAA 2148/4885
US-20250059171-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ACE, EIF2AK2 IDO1 222/4885CYP1A2 773/4885GAA 26/4885
US-20120065212-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR IDO1 3012/4885CYP1A2 84/4885GAA 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.